PriceTargets.com logo

Deciphera Pharmaceuticals - DCPH Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $24.17
  • Forecasted Upside: -5.54%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$25.59 As of 07/12/2024 01:00 AM ET
+0 (0.00%)
Get New Deciphera Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DCPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DCPH

Analyst Price Target is $24.17
▼ -5.54% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Deciphera Pharmaceuticals in the last 3 months. The average price target is $24.17, with a high forecast of $30.00 and a low forecast of $16.00. The average price target represents a -5.54% upside from the last price of $25.59.

This chart shows the closing price for DCPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 10 contributing investment analysts is to hold stock in Deciphera Pharmaceuticals. This rating has held steady since April 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/15/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
7/14/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/12/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/10/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/9/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
7/8/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/30/2024GuggenheimReiterated RatingBuy ➝ Neutral
4/30/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Perform
4/30/2024BarclaysUpgradeUnderweight ➝ Equal Weight$9.00 ➝ $26.00
4/29/2024Leerink PartnrsDowngradeOutperform ➝ Market Perform
4/29/2024Jefferies Financial GroupReiterated RatingBuy ➝ Hold$26.00 ➝ $25.60
4/29/2024JonestradingReiterated RatingBuy ➝ Hold$25.60
3/20/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$14.00 ➝ $16.00
2/7/2024Stifel NicolausBoost TargetBuy ➝ Buy$22.00 ➝ $23.00
11/20/2023JPMorgan Chase & Co.Reiterated RatingNeutral$14.00
10/31/2023Stifel NicolausBoost TargetBuy ➝ Buy$20.00 ➝ $22.00
10/31/2023JonestradingUpgradeHold ➝ Buy
10/31/2023HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $30.00
10/30/2023Piper SandlerUpgradeNeutral ➝ Overweight$18.00 ➝ $23.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$25.00
8/9/2023Stifel NicolausUpgradeHold ➝ Buy$14.00 ➝ $20.00
5/4/2023Stifel NicolausLower Target$17.00 ➝ $14.00
3/15/2023JMP SecuritiesReiterated RatingMarket Outperform$23.00
2/8/2023HC WainwrightReiterated RatingBuy$25.00
2/7/2023Leerink PartnersBoost TargetOutperform$28.00 ➝ $30.00
1/25/2023CowenBoost TargetOutperform$25.00 ➝ $30.00
1/6/2023JonestradingUpgradeSell ➝ Hold
1/4/2023Leerink PartnersBoost TargetOutperform$25.00 ➝ $28.00
1/4/2023BarclaysBoost TargetUnderweight$8.00 ➝ $9.00
1/4/2023GuggenheimUpgradeNeutral ➝ Buy$22.00
9/27/2022Stifel NicolausBoost TargetHold$11.00 ➝ $18.00
9/12/2022Leerink PartnersBoost TargetOutperform$21.00 ➝ $25.00
9/12/2022HC WainwrightBoost TargetBuy$20.00 ➝ $25.00
9/11/2022Piper SandlerBoost Target$13.00 ➝ $18.00
8/29/2022CowenInitiated CoverageOutperform$25.00
8/29/2022CowenInitiated CoverageOutperform$25.00
8/5/2022Leerink PartnersBoost TargetOutperform$15.00 ➝ $21.00
8/5/2022HC WainwrightBoost TargetBuy$15.00 ➝ $20.00
8/5/2022JMP SecuritiesUpgradeMarket Perform ➝ Outperform$23.00
2/28/2022BarclaysDowngradeEqual Weight ➝ Underweight$11.00 ➝ $6.00
12/1/2021HC WainwrightLower TargetBuy$25.00 ➝ $15.00
11/30/2021Piper SandlerLower TargetNeutral$14.00 ➝ $11.00
11/22/2021JonestradingReiterated RatingSell
11/15/2021Leerink PartnersReiterated RatingBuy$70.00
11/8/2021HC WainwrightLower TargetBuy$70.00 ➝ $25.00
11/8/2021BarclaysDowngradeOverweight ➝ Equal Weight$50.00 ➝ $11.00
11/7/2021Stifel NicolausDowngradeBuy ➝ Hold$60.00 ➝ $10.00
11/5/2021Piper SandlerDowngradeOverweight ➝ Neutral
11/5/2021GuggenheimDowngradeBuy ➝ Neutral
11/5/2021Truist FinancialDowngradeBuy ➝ Hold$65.00 ➝ $10.00
11/5/2021JMP SecuritiesLower TargetMarket Outperform$70.00 ➝ $64.00
10/4/2021Truist FinancialLower TargetBuy$84.00 ➝ $65.00
9/29/2021Stifel NicolausInitiated CoverageBuy
9/20/2021HC WainwrightReiterated RatingBuy$70.00
9/20/2021JMP SecuritiesReiterated RatingBuy$70.00
8/4/2021HC WainwrightLower TargetPositive ➝ Buy$75.00 ➝ $70.00
5/5/2021HC WainwrightLower TargetBuy$80.00 ➝ $75.00
5/5/2021BarclaysLower TargetOverweight$70.00 ➝ $65.00
5/5/2021Piper SandlerLower TargetOverweight$75.00 ➝ $60.00
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$78.00
2/10/2021BarclaysLower TargetOverweight$85.00 ➝ $70.00
2/10/2021Leerink PartnersUpgradeMarket Perform ➝ Outperform$70.00
12/2/2020Stifel NicolausInitiated CoverageBuy$75.00
11/12/2020Leerink PartnersBoost TargetMarket Perform$58.00 ➝ $70.00
9/14/2020Leerink PartnersBoost TargetMarket Perform$54.00 ➝ $58.00
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutral
8/5/2020Leerink PartnersLower TargetMarket Perform$55.00 ➝ $54.00
6/12/2020GuggenheimReiterated RatingBuy$70.00
5/18/2020SunTrust BanksBoost TargetBuy$82.00 ➝ $91.00
5/18/2020BarclaysReiterated RatingBuy$80.00 ➝ $85.00
5/7/2020Nomura InstinetDowngradeBuy ➝ Neutral$84.00 ➝ $60.00
5/6/2020NomuraDowngradeBuy ➝ Neutral$84.00 ➝ $60.00
5/6/2020JPMorgan Chase & Co.Lower TargetOverweight$50.00 ➝ $49.00
5/6/2020HC WainwrightBoost TargetBuy$60.00 ➝ $80.00
4/29/2020SunTrust BanksBoost TargetBuy$77.00 ➝ $82.00
4/29/2020Leerink PartnersBoost TargetHold$50.00 ➝ $55.00
3/4/2020BarclaysInitiated CoverageOverweight$70.00
1/22/2020Piper SandlerReiterated RatingBuy$75.00
1/21/2020Nomura SecuritiesBoost TargetBuy$57.00 ➝ $84.00
1/15/2020JMP SecuritiesReiterated RatingBuy$70.00
1/10/2020SunTrust BanksInitiated CoverageBuy$77.00
12/20/2019Piper Sandler CompaniesBoost TargetOverweight$55.00 ➝ $75.00
12/20/2019Jefferies Financial GroupBoost TargetBuy$53.00 ➝ $77.00
11/5/2019JMP SecuritiesBoost TargetOutperform ➝ Market Outperform$45.00 ➝ $54.00
10/29/2019Leerink PartnersUpgradeUnderperform ➝ Market Perform$29.00 ➝ $34.00
10/22/2019JMP SecuritiesInitiated CoverageOutperform
(Data available from 10/7/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/11/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/10/2024
  • 10 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/10/2024
  • 11 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
6/9/2024
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/8/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/7/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/7/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Deciphera Pharmaceuticals logo
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $25.59
Low: $25.59
High: $25.59

50 Day Range

MA: $25.59
Low: $25.55
High: $25.59

52 Week Range

Now: $25.59
Low: $9.90
High: $25.61

Volume

600 shs

Average Volume

1,292,551 shs

Market Capitalization

$2.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Deciphera Pharmaceuticals?

The following Wall Street research analysts have issued reports on Deciphera Pharmaceuticals in the last year: Barclays PLC, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Jonestrading, JPMorgan Chase & Co., Leerink Partnrs, Piper Sandler, and Stifel Nicolaus.
View the latest analyst ratings for DCPH.

What is the current price target for Deciphera Pharmaceuticals?

7 Wall Street analysts have set twelve-month price targets for Deciphera Pharmaceuticals in the last year. Their average twelve-month price target is $24.17, suggesting a possible downside of 5.5%. HC Wainwright has the highest price target set, predicting DCPH will reach $30.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $16.00 for Deciphera Pharmaceuticals in the next year.
View the latest price targets for DCPH.

What is the current consensus analyst rating for Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals currently has 7 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DCPH, but not buy more shares or sell existing shares.
View the latest ratings for DCPH.

What other companies compete with Deciphera Pharmaceuticals?

Other companies that are similar to Deciphera Pharmaceuticals include Agios Pharmaceuticals, Five Prime Therapeutics, Syndax Pharmaceuticals, Xencor and Seres Therapeutics. Learn More about companies similar to Deciphera Pharmaceuticals.

How do I contact Deciphera Pharmaceuticals' investor relations team?

Deciphera Pharmaceuticals' physical mailing address is 200 SMITH STREET, Waltham MA, 02451. The company's listed phone number is (781) 209-6400 and its investor relations email address is [email protected]. The official website for Deciphera Pharmaceuticals is www.deciphera.com. Learn More about contacing Deciphera Pharmaceuticals investor relations.